Editorial
doi: 10.1053/j.gastro.2018.06.053.
Epub 2018 Jul 5.
Illuminating the Black Box: The Real Risk of Serious Infection With Inflammatory Bowel Disease Therapies
Affiliations
- PMID: 29966613
- DOI: 10.1053/j.gastro.2018.06.053
Item in Clipboard
Editorial
Illuminating the Black Box: The Real Risk of Serious Infection With Inflammatory Bowel Disease Therapies
Gastroenterology.
2018 Aug.
No abstract available
Comment on
-
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12. Gastroenterology. 2018. PMID: 29655835
Similar articles
-
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.BMJ. 2015 Jun 5;350:h2809. doi: 10.1136/bmj.h2809. BMJ. 2015. PMID: 26048617 Free PMC article.
-
Risk of infections associated with biological treatment in inflammatory bowel disease.World J Gastroenterol. 2014 Nov 21;20(43):16014-9. doi: 10.3748/wjg.v20.i43.16014. World J Gastroenterol. 2014. PMID: 25473153 Free PMC article. Review.
-
Tumour necrosis factor and inflammatory bowel disease.Br J Surg. 1997 Aug;84(8):1051-8. Br J Surg. 1997. PMID: 9278640 Review.
-
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.BioDrugs. 2010 Dec 14;24 Suppl 1:1-2. doi: 10.2165/11586300-000000000-00000. BioDrugs. 2010. PMID: 21175227 No abstract available.
-
Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.Paediatr Drugs. 2018 Apr;20(2):165-171. doi: 10.1007/s40272-017-0267-8. Paediatr Drugs. 2018. PMID: 29214394
Cited by
-
Long-term outcomes of antibiotic combination therapy for ulcerative colitis.Ther Adv Chronic Dis. 2021 Jul 6;12:20406223211028790. doi: 10.1177/20406223211028790. eCollection 2021. Ther Adv Chronic Dis. 2021. PMID: 34285790 Free PMC article.
-
Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Systematic Review and Meta-Analysis of Observational Studies.J Clin Med. 2022 Jul 20;11(14):4202. doi: 10.3390/jcm11144202. J Clin Med. 2022. PMID: 35887966 Free PMC article. Review.
-
Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan.Crohns Colitis 360. 2022 Mar 21;4(2):otac010. doi: 10.1093/crocol/otac010. eCollection 2022 Apr. Crohns Colitis 360. 2022. PMID: 36777045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
